

McCord grants \$150,000 for cancer drug research

14 May 2012 | News | By BioSpectrum Bureau

McCord grants \$150,000 for cancer drug research



Singapore: McCord Research provided grants worth \$150,000 to Dr Tom Karagiannis and his team at the Baker IDI Heart and Diabetes Institute in Melbourne, Australia, in order to study the effects of its patent-pending cancer drug Olivamine. The research aims to determine the effectiveness of Olivamine against a variety of diseases including cancer, diabetes, cardiovascular disease and MS.

Dr Darlene McCord, CEO, McCord Research, said, "The grant is for one year but it is anticipated that the grant will be renewed annually."

Dr Karagiannis, whose lab has been studying the benefits of hydroxytyrosol, a major Olivamine ingredient, said that, "This is an excellent opportunity for us to expand our work in a key field of interest."

Baker IDI was established in 2008 following the merger of the Baker Heart Research Institute and the International Diabetes Institute (IDI). McCord is a R&D firm that commercializes topical and nutritional products. Its supplements are sold under the Pinnaclelife brand.